|Treatment Group (Mean Follow-Up)||Sample Size||New⁎AF/AFL||Events†per 1,000||Univariable Logistic Model||Multivariable Logistic Model‡||Kaplan-Meier Rate/1,000 Participants|
|OR||p Value||OR||p Value|
|Full trial (4.9 yrs)||6 yrs|
|Doxazosin-Chlorthalidone (3.2 yrs)||4 yrs|
|Lipid-lowering trial (4.8 yrs)||6 yrs|
The occurrence of new AF/AFL could not be ascertained in 8,025 (24.1%) of the 33,357 nondoxazosin ALLHAT participants, in 2,669 (29.5%) of the 9,061 doxazosin participants, and in 1,773 (17.1%) of the 10,355 lipid-lowering trial participants.
OR = odds ratio; other abbreviations as in Table 1.
↵⁎ There were 14 AF and 2 AFL cases among the 1,735 participants who were missing a baseline electrocardiogram but whose first follow-up electrocardiogram was negative for AF/AFL. The p value represents the probability of type I error for the 2-sided test of odds ratios' equality with unity.
↵† Age-sex-race adjusted rates; crude rates differed only for usual care (19.3/1,000) and pravastatin (19.6/1,000).
↵‡ The variables listed in Table 5were included in the multiple logistic models.